DK0631578T3 - Itraconazol- og saperconazol-stereoisomerer - Google Patents

Itraconazol- og saperconazol-stereoisomerer

Info

Publication number
DK0631578T3
DK0631578T3 DK93905338T DK93905338T DK0631578T3 DK 0631578 T3 DK0631578 T3 DK 0631578T3 DK 93905338 T DK93905338 T DK 93905338T DK 93905338 T DK93905338 T DK 93905338T DK 0631578 T3 DK0631578 T3 DK 0631578T3
Authority
DK
Denmark
Prior art keywords
itraconazole
saperconazole
stereoisomers
pharmaceutically acceptable
stereoisomer
Prior art date
Application number
DK93905338T
Other languages
Danish (da)
English (en)
Inventor
Jan Heeres
Jean-Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0631578(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0631578T3 publication Critical patent/DK0631578T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK93905338T 1992-03-18 1993-03-10 Itraconazol- og saperconazol-stereoisomerer DK0631578T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85364892A 1992-03-18 1992-03-18
PCT/EP1993/000552 WO1993019061A1 (en) 1992-03-18 1993-03-10 Itraconazole and saperconazole stereoisomers

Publications (1)

Publication Number Publication Date
DK0631578T3 true DK0631578T3 (da) 2001-08-27

Family

ID=25316567

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93905338T DK0631578T3 (da) 1992-03-18 1993-03-10 Itraconazol- og saperconazol-stereoisomerer

Country Status (21)

Country Link
US (1) US5998413A (cs)
EP (1) EP0631578B1 (cs)
KR (1) KR100243534B1 (cs)
AT (1) ATE201408T1 (cs)
AU (1) AU665988B2 (cs)
CA (1) CA2117651C (cs)
CZ (1) CZ286619B6 (cs)
DE (1) DE69330248T2 (cs)
DK (1) DK0631578T3 (cs)
ES (1) ES2158859T3 (cs)
FI (1) FI113175B (cs)
GR (1) GR3036368T3 (cs)
HU (1) HU221189B1 (cs)
NO (1) NO307786B1 (cs)
NZ (1) NZ249494A (cs)
PL (1) PL172358B1 (cs)
PT (1) PT631578E (cs)
RU (1) RU2127733C1 (cs)
SK (1) SK283118B6 (cs)
WO (1) WO1993019061A1 (cs)
ZA (1) ZA931906B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6096094A (en) * 1993-01-27 1994-08-15 Georgetown University Method and composition employing (2r,4s) itraconazole
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) * 1995-03-17 1999-09-16 Menarini Lab Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
DK0904060T3 (da) * 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed
WO1998021213A2 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,r,s- and 2s,4r,r,s-hydroxyitraconazole- and hydroxysaperconazole derivatives
EP0942907A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. 2r, 4s, s, r- and 2s, 4r, s, r-hydroxyitraconazole
CA2269608A1 (en) * 1996-11-12 1998-05-22 Sepracor Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
WO1998021205A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole
CN1244125A (zh) * 1996-11-12 2000-02-09 塞普拉科有限公司 使用顺式-羟基依他康唑以避免依他康唑和羟基依他康唑的副作用
NZ334477A (en) 1997-02-11 2001-05-25 Janssen Pharmaceutica Nv Amino acid ester containing azole antifungals
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
BR0009176A (pt) 1999-03-24 2001-12-18 Fmc Corp Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7078526B2 (en) * 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
KR100446256B1 (ko) * 2002-07-11 2004-09-01 경동제약 주식회사 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20090028938A1 (en) 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
WO2007017248A2 (en) 2005-08-08 2007-02-15 Abbott Gmbh & Co. Kg Itraconazole compositions with improved bioavailability
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
AU2012304407A1 (en) * 2011-09-09 2014-04-24 Children's Hospital & Research Center Oakland Topical itraconazole formulations and uses thereof
CN102379844A (zh) * 2011-10-31 2012-03-21 广州维美投资有限公司 一种伊曲康唑异构体注射剂
CN105061411A (zh) * 2015-06-23 2015-11-18 扬州艾迪生物科技有限公司 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4287195A (en) * 1978-07-14 1981-09-01 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) * 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) * 1987-10-21 1992-04-30 Mero Rousselot Satia Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
HUT58770A (en) * 1989-04-03 1992-03-30 Janssen Pharmaceutica Nv Process for producing regioselective substituted cyclodextrines
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
AU6096094A (en) * 1993-01-27 1994-08-15 Georgetown University Method and composition employing (2r,4s) itraconazole

Also Published As

Publication number Publication date
SK283118B6 (sk) 2003-02-04
AU665988B2 (en) 1996-01-25
NO943450D0 (no) 1994-09-16
KR950700904A (ko) 1995-02-20
FI944311L (fi) 1994-09-16
NZ249494A (en) 1996-04-26
ES2158859T3 (es) 2001-09-16
FI944311A0 (fi) 1994-09-16
SK110694A3 (en) 1995-04-12
PT631578E (pt) 2001-11-30
EP0631578B1 (en) 2001-05-23
HUT71835A (en) 1996-02-28
CZ221594A3 (en) 1995-01-18
HU9402656D0 (en) 1994-11-28
NO943450L (no) 1994-11-11
CZ286619B6 (cs) 2000-05-17
KR100243534B1 (ko) 2000-03-02
PL172358B1 (en) 1997-09-30
CA2117651C (en) 2006-01-03
HK1010729A1 (en) 1999-06-25
WO1993019061A1 (en) 1993-09-30
ZA931906B (en) 1994-09-17
US5998413A (en) 1999-12-07
DE69330248T2 (de) 2002-03-21
RU2127733C1 (ru) 1999-03-20
DE69330248D1 (de) 2001-06-28
RU94045798A (ru) 1996-07-20
EP0631578A1 (en) 1995-01-04
AU3632493A (en) 1993-10-21
FI113175B (fi) 2004-03-15
CA2117651A1 (en) 1993-09-30
HU221189B1 (en) 2002-08-28
ATE201408T1 (de) 2001-06-15
GR3036368T3 (en) 2001-11-30
NO307786B1 (no) 2000-05-29

Similar Documents

Publication Publication Date Title
DE69330248D1 (de) Itraconazol- und saperconazolstereoisomere
FI973518A7 (fi) Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
ES2183220T3 (es) Curacion de heridas y tratamientos de la fibrosis.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
US5798392C1 (en) Sulfonyl fluorides for the treatment of alzheimer's disease
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
ATE238286T1 (de) Neue triazole als therapeutische mittel gegen pilzinfektionen
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
HUP9801596A3 (en) Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
RU92015818A (ru) Способ для лечения энуреза